Corvus Pharmaceuticals, Inc. — Director's Dealing 2022

Jun 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2022-06-15

Reporting Person: CLARK IAN T (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-15	Stock Option (Right to Buy)	$0.9899	A	15000	Acquired	2032-06-15	Common Stock (15000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.